- Home
- IBRX vs IAG Comparison
IBRX vs IAG Comparison
Compare IBRX & IAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | IAG |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.5B |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | IBRX | IAG |
|---|---|---|
| Price | $8.08 | $20.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $12.57 | ★ $17.75 |
| AVG Volume (30 Days) | ★ 8.5M | 5.7M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $44.70 |
| Revenue Next Year | $131.15 | $1.11 |
| P/E Ratio | ★ N/A | $18.66 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $9.15 |
| 52 Week High | $12.43 | $24.87 |
Technical Indicators
Market Signals| Indicator | IBRX | IAG |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 67.01 |
| Support Level | $6.68 | $16.06 |
| Resistance Level | $8.46 | $22.47 |
| Average True Range (ATR) | 0.33 | 0.71 |
| MACD | 0.08 | 0.24 |
| Stochastic Oscillator | 53.00 | 75.08 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.